- Home
- KNSA vs CERT Comparison
KNSA vs CERT Comparison
Compare KNSA & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- CERT
- Stock Information
- Founded
- KNSA 2015
- CERT 2008
- Country
- KNSA United Kingdom
- CERT United States
- Employees
- KNSA N/A
- CERT N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- CERT Retail: Computer Software & Peripheral Equipment
- Sector
- KNSA Health Care
- CERT Technology
- Exchange
- KNSA Nasdaq
- CERT Nasdaq
- Market Cap
- KNSA 1.9B
- CERT 1.9B
- IPO Year
- KNSA 2018
- CERT 2020
- Fundamental
- Price
- KNSA $28.44
- CERT $10.54
- Analyst Decision
- KNSA Strong Buy
- CERT Buy
- Analyst Count
- KNSA 5
- CERT 6
- Target Price
- KNSA $38.80
- CERT $15.60
- AVG Volume (30 Days)
- KNSA 707.0K
- CERT 1.7M
- Earning Date
- KNSA 07-22-2025
- CERT 08-05-2025
- Dividend Yield
- KNSA N/A
- CERT N/A
- EPS Growth
- KNSA N/A
- CERT N/A
- EPS
- KNSA N/A
- CERT N/A
- Revenue
- KNSA $481,166,000.00
- CERT $394,498,000.00
- Revenue This Year
- KNSA $37.21
- CERT $11.57
- Revenue Next Year
- KNSA $5.32
- CERT $8.93
- P/E Ratio
- KNSA N/A
- CERT N/A
- Revenue Growth
- KNSA 59.45
- CERT 9.37
- 52 Week Low
- KNSA $17.38
- CERT $8.64
- 52 Week High
- KNSA $30.69
- CERT $16.93
- Technical
- Relative Strength Index (RSI)
- KNSA 55.24
- CERT 35.72
- Support Level
- KNSA $27.62
- CERT $10.41
- Resistance Level
- KNSA $28.69
- CERT $12.41
- Average True Range (ATR)
- KNSA 1.13
- CERT 0.52
- MACD
- KNSA -0.28
- CERT -0.10
- Stochastic Oscillator
- KNSA 45.78
- CERT 7.20
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.